This analysis of the UK NCRI Myeloma XI trial examined how age influences outcomes in newly diagnosed multiple myeloma and how the relative importance of disease-related vs patient-related factors changes over time. Among 3894 patients, older age was strongly associated with shorter progression-free and overall survival, with especially poor outcomes in patients older than 80 years. As age increased, performance status worsened, renal function declined, beta-2 microglobulin rose, and more patients fell into higher ISS stages. Although high-risk molecular abnormalities remained prognostic across age groups, their impact lessened with advancing age, while the influence of ISS increased. The findings suggest that in younger patients, tumor biology plays a larger role in determining outcome. In older patients, broader clinical factors become increasingly important.

The study also found that performance status retained prognostic value at every age, supporting the idea that physical frailty may be a more meaningful predictor of outcome than age alone. In the very elderly, some commonly used molecular risk models appeared less informative, raising concerns about relying too heavily on tumor-based risk scores in older patients. The authors argue that risk assessment and treatment planning should shift with age: younger patients may benefit most from strategies targeting high-risk disease biology, while older patients may need more individualized approaches that account for frailty, clinical condition, and treatment tolerance. Overall, the study highlights the need for age-adapted, personalized care models in multiple myeloma rather than a one-size-fits-all approach.

Reference: Pawlyn C, Cairns D, Kaiser M, et al. The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia. 2020 Feb;34(2):604-612. doi: 10.1038/s41375-019-0595-5. Epub 2019 Oct 14. PMID: 31611625; PMCID: PMC7214257.

This letter reports a small case series of five patients with multiple myeloma (MM) who later developed therapy-related myelodysplastic syndrome (t-MDS). It suggests that the seeds of t-MDS may already be present at the time MM is diagnosed. Standard next-generation sequencing did not detect myeloid mutations at the time of MM diagnosis. However, droplet digital PCR identified tiny TP53-mutant myeloid subclones in all evaluable patients, with variant allele fractions of about 0.14% to 0.20%, as many as three to eight years before t-MDS became clinically apparent. By the time t-MDS was diagnosed, all five patients had TP53-mutant myeloid clones along with monosomal karyotypes. Several also had complex karyotypes or additional mutations such as DNMT3A, TET2, RUNX1, ASXL1, and SETBP1.

The authors argue that these findings support a model in which preexisting TP53-mutant myeloid subclones are not newly caused by MM therapy, but instead are selected and expanded over time during treatment, particularly with lenalidomide exposure. In sequential samples, the investigators observed clonal evolution during MM treatment. In one patient, the TP53 subclone appeared to be selected during lenalidomide therapy rather than during several prior treatment lines. Overall, the study suggests that some patients with MM may harbor clinically silent myeloid clones years before developing t-MDS. This raises the possibility that earlier detection of TP53-mutant subclones could help identify patients at higher risk. It also may eventually inform alternative treatment strategies aimed at reducing the risk of therapy-related myeloid neoplasms.

Reference: Escure G, Fournier E, Saade C, et al. Small myeloid subclones are present at diagnosis of multiple myeloma in patients who develop secondary myelodysplastic syndromes. Haematologica. 2024 Apr 1;109(4):1289-1292. doi: 10.3324/haematol.2023.284050. PMID: 37855058; PMCID: PMC10985426.

Multiple myeloma (MM) commonly causes destructive bone disease, driven by increased osteoclast activity and reduced osteoblast response, which leads to osteolytic lesions, diffuse osteopenia, pain, fractures, spinal cord compression, hypercalcemia, renal complications, and reduced quality of life. Vertebral fractures are especially common, and the extent of bone involvement can affect both function and prognosis. Because standard skeletal surveys may miss early or smaller lesions, assessment often includes lab testing, calcium and vitamin D evaluation, and imaging such as MRI, CT, or PET/CT when clinically indicated. Overall, myeloma bone disease is a major source of morbidity. Early recognition is important to guide staging, monitor complications, and help preserve mobility and daily functioning.

Management of myeloma bone disease combines treatment of the myeloma itself with supportive strategies aimed at protecting bone health and reducing complications. Options may include systemic antimyeloma therapy, bisphosphonates, radiation, pain control, and selected procedures such as vertebroplasty, kyphoplasty, or orthopedic stabilization for fractures or high-risk lesions. The article also emphasizes the importance of addressing comorbid risks such as osteoporosis, renal disease, steroid exposure, vitamin D deficiency, inactivity, and depression. In addition, it highlights the need to educate patients about pain, symptoms of hypercalcemia, oral care during bisphosphonate therapy, and the importance of ongoing monitoring. The central message is that supportive bone care is not secondary in MM—it is a core part of treatment that can improve comfort, function, and overall quality of life.

Reference: Miceli TS, Colson K, Faiman BM, et al. Maintaining bone health in patients with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. Clin J Oncol Nurs. 2011 Aug;15 Suppl(0):9-23. doi: 10.1188/11.S1.CJON.9-23. PMID: 21816707; PMCID: PMC4189925.